Clinical Trial Finder

Clinical trial finder

The Patient Cohort of the National Center for Precision Medicine in Leukemia

Study Purpose

If for years the treatment strategy of leukemia and related disorders (LRDs, including acute leukemias and predisposition syndromes) has been based solely on whether the patient could receive or not intensive chemotherapy and transplantation, the advent of new targeted or less targeted drugs has led to the development of a growing number of new therapeutic approaches, very often offered to specific patient/disease subsets, justifying the generic term of 'precision medicine'. As an international leukemia center of excellence, THEMA, the French National Center for Precision Medicine in Leukemia (selected as IHUB-2 by the French National Agency for Research), is a care, research, transfer and education initiative located at the Saint-Louis Research Institute (IRSL) in Paris and devoted to precision medicine in leukemia in a real-life environment. The present non-interventional study (eTHEMA) is a pillar of the whole THEMA project. As a prerequisite for precision medicine, this program focuses on individual data collection, aiming to collect high-quality data not only in patients treated into prospective clinical trials, but in every THEMA patient with a special interest in outpatients' care and research. The primary objective of this non-interventional study is to describe the baseline characteristics planned treatments and outcomes of patients newly diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN)-related myelofibrosis, when managed and treated according to standard diagnosis and care practices.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient with newly diagnosed previously untreated de novo, secondary or therapy-related leukemia or related disorders (LRD), including AML, ALL, HR-MDS (according to the international score IPSS), and MNP-related myelofibrosis.
  • - Patient informed and not opposed to participating.
  • - Affiliation to social security or any health insurance.

Exclusion Criteria:

  • - LRD which is not morphologically proven (patients with granulocytic sarcoma may be included) - Previous treatment for LRD, apart from: - Hydroxyurea or previous MDS/MPN-CML therapy in AML patients.
  • - Steroids, vincristine, intrathecal prophylactic or curative injection or previous CML therapy in ALL patients.
  • - Erythroid stimulating agents (ESAs), luspatercept, granulocyte colony-stimulating factor (G-CSF), eltrombopag or other TPO agonist, iron chelation therapy, hypomethylating agents (HMAs), lenalidomide or any investigational drug previously used to treat MDS in HR-MDS patients.
  • - Hydroxyurea, standard or pegylated interferon alpha, ruxolitinib or other JAK inhibitors, busulfan, anagrelide, ESAs or any investigational drug previously used to treat MPN in MPN-related myelofibrosis patients.
  • - Patient under guardianship / curatorship.
  • - Patient under AME.
- Opposition of the patient to be enrolled in the eTHEMA cohort

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05326919
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Assistance Publique - Hôpitaux de Paris
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable
Arms & Interventions

Arms

: Acute myeloid Leukemia (AML)

Standard and routine care. For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

: Acute lymphoblastic leukemia (ALL)

Standard and routine care. For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

: High-risk myelodysplastic syndrome (MDS)

Standard and routine care. For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

: Myeloproliferative neoplasm -related myelofibrosis

Standard and routine care. For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

Interventions

Other: - Biobanking

For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hôpital Avicenne, Bobigny, France

Status

Recruiting

Address

Hôpital Avicenne

Bobigny, ,

Site Contact

Thorsten Braun, Pr

[email protected]

1 57 27 68 47

Hopital Robert Debré, Paris, France

Status

Recruiting

Address

Hopital Robert Debré

Paris, ,

Site Contact

André Baruchel, Pr

[email protected]

1 57 27 68 47

Hôpital Saint Louis, Paris, France

Status

Recruiting

Address

Hôpital Saint Louis

Paris, ,

Site Contact

Hervé Dombret, Pr

[email protected]

1 57 27 68 47 #+33